Cargando…

Improvements in health‐related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity

Previously in the SCALE Obesity and Prediabetes trial, at 1 year, participants with obesity (or overweight with comorbidities) and prediabetes receiving liraglutide 3.0 mg experienced greater improvements in health‐related quality of life (HRQoL) than those receiving placebo. The current study exten...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kolotkin, R. L., Gabriel Smolarz, B., Meincke, H. H., Fujioka, K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813214/ https://www.ncbi.nlm.nih.gov/pubmed/29045079 http://dx.doi.org/10.1111/cob.12226

Ejemplares similares

Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management
por: Kolotkin, R. L., et al.
Publicado: (2016)

Exposure–response analyses of liraglutide 3.0 mg for weight management
por: Wilding, J. P. H., et al.
Publicado: (2016)

Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis
por: Konwar, Mahanjit, et al.
Publicado: (2022)

Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis
por: Overgaard, Rune V., et al.
Publicado: (2016)

The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg
por: Mancini, Marcio C., et al.
Publicado: (2017)

Real‐World Clinical Effectiveness of Liraglutide 3.0 mg for Weight Management in Canada
por: Wharton, Sean, et al.
Publicado: (2019)

The Efficacy and Safety of Liraglutide 3.0 mg for Weight Management in Obese Non-Diabetic Saudi Outpatients
por: Albaker, Waleed, et al.
Publicado: (2021)

Adherence to and Dropout from Liraglutide 3.0 mg Obesity Treatment in a Real-World Setting
por: Ko, Hae-Jin, et al.
Publicado: (2022)

Early Weight Loss with Liraglutide 3.0 mg Predicts 1‐Year Weight Loss and is Associated with Improvements in Clinical Markers
por: Fujioka, Ken, et al.
Publicado: (2016)

A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder
por: Allison, Kelly C., et al.
Publicado: (2022)

Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada
por: Wharton, Sean, et al.
Publicado: (2020)

Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a Swiss cohort with obesity
por: Santini, Sara, et al.
Publicado: (2022)

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
por: Garvey, W. Timothy, et al.
Publicado: (2020)

Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
por: Wadden, Thomas A., et al.
Publicado: (2020)

Real‐world persistence with liraglutide 3.0 mg for weight management and the SaxendaCare® patient support program
por: Wharton, Sean, et al.
Publicado: (2020)

Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post‐bariatric surgery
por: Wharton, Sean, et al.
Publicado: (2019)

Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery
por: Muratori, Fabrizio, et al.
Publicado: (2022)

Neuropsychiatric safety with liraglutide 3.0 mg for weight management: Results from randomized controlled phase 2 and 3a trials
por: O'Neil, Patrick M., et al.
Publicado: (2017)

SAT-099 Liraglutide 3.0 mg as an Adjunct to Intensive Behavior Therapy in Individuals with Obesity: SCALE IBT 56-Week Randomized, Double-Blind, Placebo-Controlled Trial
por: Wadden, Thomas, et al.
Publicado: (2019)

Impact of Treatment with GLP1 Receptor Agonists, Liraglutide 3.0 mg and Semaglutide 1.0 mg, While on a Waiting List for Bariatric Surgery
por: Rubio-Herrera, Miguel A., et al.
Publicado: (2023)

SAT-097 Weight Loss With Liraglutide 3.0 Mg Versus Placebo For Individuals Who Adhere To The Trial Drug: A Secondary Analysis From SCALE IBT
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
por: Blackman, A, et al.
Publicado: (2016)

Safety and Efficacy of Liraglutide, 3.0 mg, Once Daily vs Placebo in Patients With Poor Weight Loss Following Metabolic Surgery: The BARI-OPTIMISE Randomized Clinical Trial
por: Mok, Jessica, et al.
Publicado: (2023)

SAT-105 Weight Loss As Determined By Adherence To Reduced Caloric Diet, Increased Physical Activity, Liraglutide 3.0 Mg and Placebo: A Sub-analysis Of The SCALE IBT Trial
por: Shaw Tronieri, Jena, et al.
Publicado: (2019)

Impact of dose‐escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model‐based approach
por: Papathanasiou, Theodoros, et al.
Publicado: (2020)

Improving Adherence to Weight‐Loss Medication (Liraglutide 3.0 mg) Using Mobile Phone Text Messaging and Healthcare Professional Support
por: Li, Ang, et al.
Publicado: (2020)

Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit
por: Tempia Valenta, Silvia, et al.
Publicado: (2023)

Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials
por: Ard, J., et al.
Publicado: (2016)

Effects of liraglutide on gallbladder emptying: A randomized, placebo‐controlled trial in adults with overweight or obesity
por: Nexøe‐Larsen, Christina C., et al.
Publicado: (2018)

MON-120 Effect of Weight Loss on Physical Function Measured by the 6-Minute Walking Distance Test in Individuals with Obesity: Results from the SCALE IBT Trial of Liraglutide 3.0 Mg
por: Rubino, Domenica, et al.
Publicado: (2019)

Effectiveness and cost of integrating a pragmatic pathway for prescribing liraglutide 3.0 mg in obesity services (STRIVE study): study protocol of an open-label, real-world, randomised, controlled trial
por: Papamargaritis, Dimitris, et al.
Publicado: (2020)

Benefits of Liraglutide Treatment in Overweight and Obese Older Individuals With Prediabetes
por: Kim, Sun H., et al.
Publicado: (2013)

An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
por: Pratley, Richard E., et al.
Publicado: (2021)

An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression
por: Lingvay, Ildiko, et al.
Publicado: (2021)

A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg
por: Seino, Yutaka, et al.
Publicado: (2022)

Marketing 3.0 /
por: Kotler, Philip
Publicado: (2018)

Delphi 3.0
por: Charte Ojeda, Francisco
Publicado: (1998)

Talent 3.0
por: Díaz-Llairó, Amparo
Publicado: (2017)

Manager 3.0
por: Karsh, Brad
Publicado: (2013)

Development of a clinical trials version of the Impact of Weight on Quality of Life‐Lite questionnaire (IWQOL‐Lite Clinical Trials Version): results from two qualitative studies
por: Kolotkin, R. L., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_v9jlvuf4866nmgupm8sejt6hhs